Home › Research › Risk factors
Progressive Supranuclear Palsy—A Global Review
Prashanth Lingappa Kukkle, Rosy Neupane, Alexander Y. Pantelyat, Anne-Marie A. Wills, Edwin Jabbari, Elise G.P. Dopper, Gábor Géza Kovács, Günter U. Höglinger et al.. Movement Disorders Clinical Practice, 2025-09-03
Topic: Risk, prevention and care in population studies
Global PSP prevalence ranges between 5-6.4 per 100,000, influenced by diagnostic criteria and healthcare infrastructure. Clinical manifestations commonly include supranuclear gaze palsy, frequent falls, cognitive impairment, and motor dysfunction. Prognosis significantly varies with subtype; PSP-RS shows rapid progression and shorter survival (5-7 years), whereas PSP-P has a milder clinical course (8-12 years). Regional variations highlight differences in genetic predispositions, notably the MAPT H1 haplotype, environmental risk factors such as dietary neurotoxins and industrial pollutants, and accessibility to comprehensive healthcare services. Diagnostic accuracy has improved with the adoption of MDS-PSP criteria, facilitating recognition of diverse phenotypes. Regional disparities in PSP prevalence, phenotypic presentation, and healthcare accessibility underscore the importance of standardized diagnostic criteria, targeted genetic and environmental studies, and equitable healthcare strategies. Enhanced global collaboration is essential for improving PSP diagnosis, management, and patient outcomes worldwide.
Key findings
- Global PSP prevalence ranges between 5-6.4 per 100,000, influenced by diagnostic criteria and healthcare infrastructure.
- Clinical manifestations commonly include supranuclear gaze palsy, frequent falls, cognitive impairment, and motor dysfunction.
- Prognosis significantly varies with subtype; PSP-RS shows rapid progression and shorter survival (5-7 years), whereas PSP-P has a milder clinical course (8-12 years).
- Regional variations highlight differences in genetic predispositions, notably the MAPT H1 haplotype, environmental risk factors such as dietary neurotoxins and industrial pollutants, and accessibility to comprehensive healthcare services.
- Diagnostic accuracy has improved with the adoption of MDS-PSP criteria, facilitating recognition of diverse phenotypes.
Why it matters
This global review describes how common progressive supranuclear palsy is, its symptoms, and how it varies by subtype and region. It is about PSP, not Alzheimer's disease, and does not report any treatment, cure, or prevention.
New to this subject? Start with our plain-English guide: Risk factors, ranked →
Study details
- Evidence strengthLow
How this study scored 42/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomised / blinded because the record does not state it. We have no data on senior author's track record, so that was left out: it earned 40 of the 96 points we could judge it on, which is 42 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Movement Disorders Clinical Practice) |
| Journal's citation record | 0 / 4 | Movement Disorders Clinical Practice: journal h-index 59 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomised / blinded | 0 / 2 | No randomisation or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 2 / 7 | Cited 12 times (OpenAlex, 2026-10-10) |
| Citations per year | 2 / 5 | 4.0 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 3 / 6 | Cited 6.8× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 1 / 4 | Cited 12 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | 3 / 3 | Harvard University: institution h-index 3,235 (OpenAlex) |
| Multi-centre collaboration | 3 / 3 | OpenAlex lists 21 institution(s) in 11 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 40898879) |
| Free to read | 2 / 2 | Free to read |
| Points | 40 / 96 | Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 40 of the 96 points we could judge it on is 42 out of 100. |
| Total | 42 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1002/mdc3.70338
- PubMed: 40898879
- Original source →
- Free full text: EUR Research Repository (Erasmus University Rotterdam) →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
APA 7th
Kukkle, P. L., Neupane, R., Pantelyat, A. Y., Wills, A.-M. A., Jabbari, E., Dopper, E. G., et al. (2025). Progressive Supranuclear Palsy—A Global Review. Movement Disorders Clinical Practice. https://doi.org/10.1002/mdc3.70338
Vancouver
Kukkle PL, Neupane R, Pantelyat AY, Wills A.-MA, Jabbari E, Dopper EG, et al. Progressive Supranuclear Palsy—A Global Review. Movement Disorders Clinical Practice. 2025. doi:10.1002/mdc3.70338. PMID: 40898879.
BibTeX
@article{kukkle2025-40898879,
author = {Kukkle, Prashanth Lingappa and Neupane, Rosy and Pantelyat, Alexander Y. and Wills, Anne-Marie A. and Jabbari, Edwin and Dopper, Elise G.P. and Kovács, Gábor Géza and Höglinger, Günter U. and others},
title = {{Progressive Supranuclear Palsy—A Global Review}},
journal = {Movement Disorders Clinical Practice},
year = {2025},
doi = {10.1002/mdc3.70338},
pmid = {40898879},
url = {https://doi.org/10.1002/mdc3.70338}
}
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Related studies in Risk factors
Also in Risk factors
356 studies in the library are filed under Risk factors with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Risk factors hub.